Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | HTT | P42858 | 3/20 | 0.70 |
| ▸ | XBP1 | P17861 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SPR | P35270 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14299385 | 1.00 | ALDH1A1 (0.70) | ALDH1A1HTTXBP1RAB9AMEN1 | |
| SCHEMBL5969847 | 0.90 | ALDH1A1 (0.57) | ALDH1A1HTTXBP1RAB9AMEN1 | |
| SCHEMBL5969786 | 0.90 | ALDH1A1 (0.57) | ALDH1A1HTTXBP1RAB9AMEN1 | |
| SCHEMBL9957488 | 0.86 | ALDH1A1 (0.72) | ALDH1A1HTTXBP1RAB9AMEN1 | |
| SCHEMBL8231768 | 0.86 | ALDH1A1 (0.72) | ALDH1A1HTTXBP1RAB9AMEN1 | |
| SCHEMBL11743947 | 0.86 | ALDH1A1 (0.68) | ALDH1A1HTTXBP1RAB9AMEN1 | |
| SCHEMBL9490252 | 0.84 | HTT (0.58) | ALDH1A1HTTXBP1RAB9AMEN1 | |
| SCHEMBL18701634 | 0.84 | ALDH1A1 (0.65) | ALDH1A1HTTXBP1RAB9AMEN1 | |
| SCHEMBL18711851 | 0.84 | ALDH1A1 (0.65) | ALDH1A1HTTXBP1RAB9AMEN1 | |
| SCHEMBL19658774 | 0.84 | ALDH1A1 (0.78) | ALDH1A1HTTXBP1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3356345-B1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-11-08 | — | — | EP | disclosed |
| US-10703754-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | ELI LILLY AND COMPANY (US) | 2020-07-07 | — | — | US | disclosed |
| WO-2019178248-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-19 | — | — | WO | disclosed |
| US-20190194202-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELI LILLY AND COMPANY | 2019-06-27 | — | — | US | disclosed |
| US-20180265511-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELI LILLY AND COMPANY | 2018-09-20 | — | — | US | disclosed |
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2018-05-17 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-8835427-B2 | Fungicidal heterocyclic compounds | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835427-B2 | Fungicidal heterocyclic compounds | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-09-16 | — | — | US | disclosed |
| WO-2011085170-A1 | FUNGICIDAL HETEROCYCLIC COMPOUNDS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-07-14 | — | — | WO | disclosed |
| US-7776897-B2 | such as 3-[1-(5-chloro-2-thienyl)cyclopenty]-5,6,7,8,9,10-hexahydro [1,2,4]triazolo[4,3-a]azocine, having a strong 11 beta -hydroxysteroid dehydrogenase type 1inhibitory activity and exhibiting an excellent blood-glucose level-lowering action, used for the therapy of diabetes and insulin resistance | ASTELLAS PHARMA INC. (JP) | 2010-08-17 | — | — | US | disclosed |
| WO-2010065579-A2 | FUNGICIDAL HETEROCYCLIC COMPOUNDS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20090143377-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2009-06-04 | — | — | US | disclosed |
| US-20070259854-A1 | Triazole Derivative or Salt Thereof | ASTELLAS PHARMA INC. (JP) | 2007-11-08 | — | — | US | disclosed |
| WO-2007119247-A2 | IMPROVED MANUFACTURING PROCEDURE FOR THE PREPARATION OF POLYMORPHIC FORM II OF CIS-(1S)-N-METHYL-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHLENEAMINE HYDROCHLORIDE (SERTRALINE HYDROCHLORIDE) | UNICHEM LABORATORIES LIMITED (IN) | 2007-10-25 | — | — | WO | disclosed |
| US-5463126-A | Process for preparing sertraline | PFIZER INC. (US) | 1995-10-31 | — | — | US | disclosed |
| EP-0594666-B1 | PROCESS FOR PREPARING SERTRALINE | PFIZER LTD (GB) | 1995-09-13 | — | — | EP | disclosed |
| WO-1993001162-A1 | PROCESS FOR PREPARING SERTRALINE | PFIZER LIMITED (GB) | 1993-01-21 | — | — | WO | disclosed |
| US-4089976-A | Synthesis of 1,2,3,4-tetrahydro-4-oxo-[or oxy-]-1-naphthylureas as novel growth-promoting compounds for animals | AMERICAN CYANAMID COMPANY (US) | 1978-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10703754-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | ELANE, CASP3, MMP8 | ALDH1A1 1104/4885HTT 4377/4885XBP1 3335/4885 |
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | ALDH1A1 968/4885HTT 160/4885XBP1 528/4885 |
| US-20180265511-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | ALDH1A1 1104/4885HTT 4377/4885XBP1 3335/4885 |
| US-20090143377-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | ALDH1A1 968/4885HTT 160/4885XBP1 528/4885 |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | ALDH1A1 374/4885HTT 4284/4885XBP1 3669/4885 |
| US-20070259854-A1 | Triazole Derivative or Salt Thereof | HSD11B1, HSD11B2, HSD3B1 | ALDH1A1 288/4885HTT 2559/4885XBP1 2105/4885 |
| US-20190194202-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | ALDH1A1 1104/4885HTT 4377/4885XBP1 3335/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | ALDH1A1 1563/4885HTT 832/4885XBP1 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.